72 results on '"Azap O"'
Search Results
2. European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease
- Author
-
Ergönül, Mehmet Önder (ORCID 0000-0003-1935-9235 & YÖK ID 110398), Bartoletti, M.; Azap, O.; Barac, A.; Bussini, L.; Krause, R.; Martin Quiros, A.; Paño-Pardo, J.R.; Power, N.; Sibani, M.; Szabo, B.G.; Tsiodras, S.; Zollner-Schwetz, I.; Rodríguez-Baño, J., Koç Üniversitesi İş Bankası Enfeksiyon Hastalıkları Uygulama ve Araştırma Merkezi (EHAM) / Koç University İşbank Center for Infectious Diseases (KU-IS CID), Koç University Hospital, School of Medicine, Ergönül, Mehmet Önder (ORCID 0000-0003-1935-9235 & YÖK ID 110398), Bartoletti, M.; Azap, O.; Barac, A.; Bussini, L.; Krause, R.; Martin Quiros, A.; Paño-Pardo, J.R.; Power, N.; Sibani, M.; Szabo, B.G.; Tsiodras, S.; Zollner-Schwetz, I.; Rodríguez-Baño, J., Koç Üniversitesi İş Bankası Enfeksiyon Hastalıkları Uygulama ve Araştırma Merkezi (EHAM) / Koç University İşbank Center for Infectious Diseases (KU-IS CID), Koç University Hospital, and School of Medicine
- Abstract
Scope: despite the large availability of vaccines, coronavirus disease 2019 (COVID-19), induced by severe acute respiratory syndrome coronavirus 2, continues to be a major threat for health-care providers and fragile people. A number of options are now available for outpatients with mild-to-moderate COVID-19 at the risk of disease progression for the prevention of deaths or hospitalization. Methods: a European Society of Clinical Microbiology and Infectious Diseases COVID-19 guidelines task force was established by the European Society of Clinical Microbiology and Infectious Diseases Executive Committee. A small group was established, half appointed by the chair and the remaining selected based on an open call. Each panel met virtually once a week. For all decisions, a simple majority vote was used. A long list of clinical questions using the population, intervention, comparison, outcome format was developed at the beginning of the process. For each population, intervention, comparison, outcome, two panel members performed a literature search, with a third panelist involved in case of inconsistent results. Voting was based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Recommendations: in this update, we focus on anti-viral agents, monoclonal antibodies (mAbs) and other treatment options proposed for patients with mild or moderate COVID-19 who are at the risk of hospitalization or death. Although the use of anti-virals is recommended, especially nirmatrelvir/ritonavir and remdesivir or, alternatively, molnupirarvir, the administration of mAbs against the spike protein strictly depends on circulating variants or the ability to test timely for variants and sub-variants. At the time of writing (April–June 2022), the only active mAb was tixagevimab/cilgavimab given the predominance of the Omicron BA.2, BA.3, BA.4 and BA.5 sub-lineages in Europe. However, considering that the epidemiological scenario is extremely dynamic, const, NA
- Published
- 2022
3. Inappropriate use of ivermectin during the COVID-19 pandemic: primum non nocere!
- Author
-
Barac, A. Bartoletti, M. Azap, O. Bussini, L. Ergonul, O. Krause, R. Paño-Pardo, J.R. Power, N.R. Rodríguez-Baño, J. Sibani, M. Szabo, B.G. Tsiodras, S. Verweij, P.E. Quirós, A.M. Zollner-Schwetz, I.
- Published
- 2022
4. Comparison of the risk factors for Candida albicans versus other Candida spp. bloodstream infections in intensive care unit patients: O456
- Author
-
Timurkaynak, F., Azap, O. Kurt, Senger, S. Serin, Cagir, U., and Arslan, H.
- Published
- 2008
5. Etiologic agents of diarrhea in solid organ recipients
- Author
-
Arslan, H., Inci, E. K., Azap, O. K., Karakayali, H., Torgay, A., and Haberal, M.
- Published
- 2007
6. Biofilm formation of nosocomial Acinetobacter baumannii strains: P1652
- Author
-
Can, F., Azap, O. Kurt, Demirbilek, M., Timurkaynak, F., Karabay, G., and Arslan, H.
- Published
- 2005
7. Biofilm production and antifungal susceptibility patterns of Candida species isolated from hospitalised patients: P1161
- Author
-
Demirbilek, M., Timurkaynak, F., Can, F., Azap, O. Kurt, and Arslan, H.
- Published
- 2005
8. Comparitive in vitro activities of ciprofloxacin, ofloxacin and levofloxacin against nonfermentative bacteria isolated from nosocomial infections
- Author
-
Ergin, F., Arslan, H., Azap, O. Kurt, Karaman, S., and Yapar, G.
- Published
- 2004
9. In vitro activities of non-traditional antimicrobials against multiresistant strains of P. aeruginosa and A. baumanii isolated from intensive care units
- Author
-
Arslan, H., Azap, O. Kurt, Ergin, F., Karaman, S. Ozbalikci, Oruç, E., Can, F., and Demirbilek, M.
- Published
- 2004
10. Synergistic activities of nontraditional antibiotic combinations against multiresistant Pseudomonas aeruginosa and Acinetobacter baumannii strains
- Author
-
Can, F., Ergin, F., Demirbilek, M., Azap, O. Kurt, and Arslan, H.
- Published
- 2004
11. Determination of minimal inhibitory concentration of trimethoprim sulfamethoxazole against Stenotrophomonas maltophilia
- Author
-
Azap, O. Kurt, Timurkaynak, F. Ergin, Arslan, H., Inci, E. Kuru, and Yapar, G.
- Published
- 2003
12. Evaluation of diarrhea episodes in renal transplantation patients
- Author
-
Arslan, H., Timurkaynak, F., Azap, O. Kurt, Yapar, G., Moray, G., and Haberal, M.
- Published
- 2003
13. Detection of extended spectrum beta-lactamase among Acinetobacter baumanii strains
- Author
-
Timurkaynak, F., Azap, O. Kurt, Arslan, H., Inci, E. Kuru, Karaman, S., and Yapar, G.
- Published
- 2003
14. The role of AcrAB-TolC Efflux pumps on quinolone resistance of E-coli ST131
- Author
-
Ergönül, Mehmet Önder (ORCID 0000-0003-1935-9235 & YÖK ID 110398); Ataç, Nazlı; Gönen, Mehmet (ORCID 0000-0002-2483-075X & YÖK ID 237468), Kurt-Azap, O.; Dolapcı, I.; Yeşilkaya, A.; Can, F., School of Medicine; College of Engineering, Department of Clinical Microbiology and Infectious Diseases; Department of Industrial Engineering, Ergönül, Mehmet Önder (ORCID 0000-0003-1935-9235 & YÖK ID 110398); Ataç, Nazlı; Gönen, Mehmet (ORCID 0000-0002-2483-075X & YÖK ID 237468), Kurt-Azap, O.; Dolapcı, I.; Yeşilkaya, A.; Can, F., School of Medicine; College of Engineering, and Department of Clinical Microbiology and Infectious Diseases; Department of Industrial Engineering
- Abstract
Escherichia coli ST131 is a cause for global concern because of its high multidrug resistance and several virulence factors. In this study, the contribution of acrAB-TolC efflux system of E. coli ST131 to fluoroquinolone resistance was evaluated. A total of nonrepetitive 111 ciprofloxacin-resistant E. coli isolates were included in the study. Multilocus sequence typing was used for genotyping. Expressions of acrA, acrB, and TolC efflux pump genes were measured by RT-PCR. Mutations in marA, gyrA, parC, and aac(6)-lb-cr positivity were studied by Sanger sequencing. Sixty-four (57.7%) of the isolates were classified as ST131, and 52 (81.3%) of the ST131 isolates belonged to H30-Rx subclone. In ST131, CTX-M 15 positivity (73%) and aac(6)-lb-cr carriage (75%) were significantly higher than those in non-ST131 (12.8% and 51%, respectively) (P<0.05). The ampicillin-sulbactam (83%) resistance was higher, and gentamicin resistance (20%) was lower in ST131 than that in non-ST131 (64% and 55%, respectively) (P=0.001 and P=0.0002). Numbers of the isolates with MDR or XDR profiles did not differ in both groups. Multiple in-dels (up to 16) were recorded in all quinolone-resistant isolates. However, marA gene was more overexpressed in ST131 compared to that in non-ST131 (median 5.98 vs. 3.99; P=0.0007). Belonging to H30-Rx subclone, isolation site, ciprofloxacin MIC values did not correlate with efflux pump expressions. In conclusion, the marA regulatory gene of AcrAB-TolC efflux pump system has a significant impact on quinolone resistance and progression to MDR profile in ST131 clone. Efflux pump inhibitors might be alternative drugs for the treatment of infections caused by E. coli ST131 if used synergistically in combination with antibiotics., NA
- Published
- 2018
15. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
- Author
-
Gutierrez-Gutierrez, B., Salamanca, E., de Cueto, M., Hsueh, P. -R., Viale, P., Pano-Pardo, J. R., Venditti, M., Tumbarello, M., Daikos, G., Canton, R., Doi, Y., Tuon, F. F., Karaiskos, I., Perez-Nadales, E., Schwaber, M. J., Azap, O. K., Souli, M., Roilides, E., Pournaras, S., Akova, M., Perez, F., Bermejo, J., Oliver, A., Almela, M., Lowman, W., Almirante, B., Bonomo, R. A., Carmeli, Y., Paterson, D. L., Pascual, A., Rodriguez-Bano, J., del Toro, M. D., Galvez, J., Falcone, M., Russo, A., Giamarellou, H., Trecarichi, E. M., Losito, A. R., Garcia-Vazquez, E., Hernandez, A., Gomez, J., Bou, G., Iosifidis, E., Prim, N., Navarro, F., Mirelis, B., Skiada, A., Origuen, J., Juan, R. S., Fernandez-Ruiz, M., Larrosa, N., Puig-Asensio, M., Cisneros, J. M., Molina, J., Gonzalez, V., Rucci, V., de Gopegui, E. R., Marinescu, C. I., Martinez-Martinez, L., Farinas, M. C., Cano, M. E., Gozalo, M., Mora-Rillo, M., Francisco, C. N. -S., Pena, C., Gomez-Zorrilla, S., Tubau, F., Tsakris, A., Zarkotou, O., Antoniadou, A., Poulakou, G., Pitout, J., Virmani, D., Torre-Cisneros, J., Guzman-Puche, J., Helvaci, O., Sahin, A. O., Pintado, V., Ruiz, P., Bartoletti, M., Giannella, M., Tacconelli, E., Riemenschneider, F., Calbo, E., Badia, C., Xercavins, M., Gasch, O., Fontanals, D., Jove, E., Venditti M., Tumbarello M. (ORCID:0000-0002-9519-8552), Trecarichi E. M., Losito A. R., Tacconelli E. (ORCID:0000-0001-8722-5824), Gutierrez-Gutierrez, B., Salamanca, E., de Cueto, M., Hsueh, P. -R., Viale, P., Pano-Pardo, J. R., Venditti, M., Tumbarello, M., Daikos, G., Canton, R., Doi, Y., Tuon, F. F., Karaiskos, I., Perez-Nadales, E., Schwaber, M. J., Azap, O. K., Souli, M., Roilides, E., Pournaras, S., Akova, M., Perez, F., Bermejo, J., Oliver, A., Almela, M., Lowman, W., Almirante, B., Bonomo, R. A., Carmeli, Y., Paterson, D. L., Pascual, A., Rodriguez-Bano, J., del Toro, M. D., Galvez, J., Falcone, M., Russo, A., Giamarellou, H., Trecarichi, E. M., Losito, A. R., Garcia-Vazquez, E., Hernandez, A., Gomez, J., Bou, G., Iosifidis, E., Prim, N., Navarro, F., Mirelis, B., Skiada, A., Origuen, J., Juan, R. S., Fernandez-Ruiz, M., Larrosa, N., Puig-Asensio, M., Cisneros, J. M., Molina, J., Gonzalez, V., Rucci, V., de Gopegui, E. R., Marinescu, C. I., Martinez-Martinez, L., Farinas, M. C., Cano, M. E., Gozalo, M., Mora-Rillo, M., Francisco, C. N. -S., Pena, C., Gomez-Zorrilla, S., Tubau, F., Tsakris, A., Zarkotou, O., Antoniadou, A., Poulakou, G., Pitout, J., Virmani, D., Torre-Cisneros, J., Guzman-Puche, J., Helvaci, O., Sahin, A. O., Pintado, V., Ruiz, P., Bartoletti, M., Giannella, M., Tacconelli, E., Riemenschneider, F., Calbo, E., Badia, C., Xercavins, M., Gasch, O., Fontanals, D., Jove, E., Venditti M., Tumbarello M. (ORCID:0000-0002-9519-8552), Trecarichi E. M., Losito A. R., and Tacconelli E. (ORCID:0000-0001-8722-5824)
- Abstract
Background The best available treatment against carbapenemase-producing Enterobacteriaceae (CPE) is unknown. The objective of this study was to investigate the effect of appropriate therapy and of appropriate combination therapy on mortality of patients with bloodstream infections (BSIs) due to CPE. Methods In this retrospective cohort study, we included patients with clinically significant monomicrobial BSIs due to CPE from the INCREMENT cohort, recruited from 26 tertiary hospitals in ten countries. Exclusion criteria were missing key data, death sooner than 24 h after the index date, therapy with an active antibiotic for at least 2 days when blood cultures were taken, and subsequent episodes in the same patient. We compared 30 day all-cause mortality between patients receiving appropriate (including an active drug against the blood isolate and started in the first 5 days after infection) or inappropriate therapy, and for patients receiving appropriate therapy, between those receiving active monotherapy (only one active drug) or combination therapy (more than one). We used a propensity score for receiving combination therapy and a validated mortality score (INCREMENT-CPE mortality score) to control for confounders in Cox regression analyses. We stratified analyses of combination therapy according to INCREMENT-CPE mortality score (0–7 [low mortality score] vs 8–15 [high mortality score]). INCREMENT is registered with ClinicalTrials.gov, number NCT01764490. Findings Between Jan 1, 2004, and Dec 31, 2013, 480 patients with BSIs due to CPE were enrolled in the INCREMENT cohort, of whom we included 437 (91%) in this study. 343 (78%) patients received appropriate therapy compared with 94 (22%) who received inappropriate therapy. The most frequent organism was Klebsiella pneumoniae (375 [86%] of 437; 291 [85%] of 343 patients receiving appropriate therapy vs 84 [89%] of 94 receiving inappropriate therapy) and the most frequent carbapenemase was K pneumoniae carbapenemase
- Published
- 2017
16. Emerging Escherichia coli O25b/ST131 Clone Predicts Treatment Failure in Urinary Tract Infections
- Author
-
Can, F., primary, Azap, O. K., additional, Seref, C., additional, Ispir, P., additional, Arslan, H., additional, and Ergonul, O., additional
- Published
- 2014
- Full Text
- View/download PDF
17. 833 The Effect of Probiotics on Colonization of Resistant Organisms in Preterm Infants
- Author
-
Kurt, A., primary, Ecevit, A., additional, Ince, D. A., additional, Abbasoglu, A., additional, Azap, O. K., additional, Ecevit, Z., additional, Ogus, E., additional, and Tarcan, A., additional
- Published
- 2012
- Full Text
- View/download PDF
18. R2289 Epidemiology of candidaemia and antifungal susceptibility patterns in a Turkish university hospital
- Author
-
Serin Senger, S., primary, Demirbilek, M., additional, Kurt Azap, O., additional, Timurkaynak, F., additional, and Arslan, H., additional
- Published
- 2007
- Full Text
- View/download PDF
19. P2104 Surgical antibiotic prophylaxis in a Turkish university hospital
- Author
-
Serin Senger, S., primary, Togan, T., additional, Kurt Azap, O., additional, Timurkaynak, F., additional, and Arslan, H., additional
- Published
- 2007
- Full Text
- View/download PDF
20. P2034 In vitro antibacterial activity of tigecycline in comparison with doxycycline, ciprofioxacin and rifampin against Brucella species
- Author
-
Turan, H., primary, Arslan, H., additional, Uncu, H., additional, Azap, O., additional, and Serefhanoglu, K., additional
- Published
- 2007
- Full Text
- View/download PDF
21. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units
- Author
-
TIMURKAYNAK, F, primary, CAN, F, additional, AZAP, O, additional, DEMIRBILEK, M, additional, ARSLAN, H, additional, and KARAMAN, S, additional
- Published
- 2006
- Full Text
- View/download PDF
22. Gemella morbillorum peritonitis in a patient being treated with continuous ambulatory peritoneal dialysis
- Author
-
Azap, O. K., primary, Yapar, G., additional, Timurkaynak, F., additional, Arslan, H., additional, Sezer, S., additional, and Ozdemir, N., additional
- Published
- 2005
- Full Text
- View/download PDF
23. 138 Bloodstream infections in burn patients
- Author
-
Serin Senger, S., Azap, O., Timurkaynak, F., Kursun, E., Arslan, H., Basaran, O., and Haberal, M.
- Published
- 2006
- Full Text
- View/download PDF
24. 22 Cytomegalovirus infections in solid organ transplant recipients
- Author
-
Timurkaynak, F., Kurt Azap, O., Arslan, H., Kursun, E., Demirhan, B., and Haberal, M.
- Published
- 2006
- Full Text
- View/download PDF
25. A fatal case of West Nile virus encephalitis,Ölümcül seyreden Bati Nil virusu ensefaliti olgusu
- Author
-
Yeşilkaya, A., Kurt Azap, O., Ayse Hande Arslan, Yaǧci Çaǧlayik, D., Uyar, Y., Korukluoǧlu, G., and Özkul, A.
26. Invasive fungal infections in liver recipients
- Author
-
Azap, O. Kurt, Kursun, E., Timurkaynak, F., Arslan, H., Demirhan, B., and Mehmet Haberal
27. Spondylodiscitis and endocarditis caused by S. vestibularis
- Author
-
Muge Aydin Tufan, MD, Kart-Koseoglu Hamide, Associate Professor, Ersozlu-Bozkirli Duygu, MD, Azap Ozlem, Associate Professor, Tufan Kadir, MD, and Yucel Ahmet Eftal, Professor
- Subjects
Infectious and parasitic diseases ,RC109-216 ,Microbiology ,QR1-502 - Abstract
Streptococcus vestibularis is a recently described member of the viridans group that was first isolated from the vestibular mucosa of the human oral cavity and described as a new species in 1988. It has been rarely associated with human infections. In few papers, it has been reported as a causal agent of systemic infection in immunosupressed adults and in those with other severe underlying diseases, like coronary valve diseases. A 65-year-old woman was admitted to the hospital with complaints of fever for three months, general malaise, effort dyspnea, weight loss, back pain and myalgia. Both native aortic valve endocarditis and spondylodiscitis due to Streptococcus vestibularis were detected. The patient was successfully treated with intravenous potassium penicillin G and gentamicin for six weeks, followed by oral amoxicillin for three months, in addition to aortic valve replacement. In all patients with spondylodiscitis, infective endocarditis should be considered, particularly in patients with heart valve disease history, since spondylodiscitis may be the presenting sign of an infective endocarditis. Cardiac valve replacement surgery should be performed if the course of fever and inflammatory syndrome is unfavorable after appropriate antibiotic treatment. We report the first case with both native aortic valve endocarditis and spondylodiscitis due to Streptococcus vestibularis. Keywords: endocarditis, spondylodiscitis, Streptococcus vestibularis
- Published
- 2010
- Full Text
- View/download PDF
28. Spondylodiscitis and endocarditis caused by S. vestibularis
- Author
-
Muge Aydin Tufan, Kart-Koseoglu Hamide, Ersozlu-Bozkirli Duygu, Azap Ozlem, Tufan Kadir, and Yucel Ahmet Eftal
- Subjects
endocarditis ,spondylodiscitis ,Streptococcus vestibularis ,Infectious and parasitic diseases ,RC109-216 ,Microbiology ,QR1-502 - Abstract
Streptococcus vestibularis is a recently described member of the viridans group that was first isolated from the vestibular mucosa of the human oral cavity and described as a new species in 1988. It has been rarely associated with human infections. In few papers, it has been reported as a causal agent of systemic infection in immunosupressed adults and in those with other severe underlying diseases, like coronary valve diseases. A 65-year-old woman was admitted to the hospital with complaints of fever for three months, general malaise, effort dyspnea, weight loss, back pain and myalgia. Both native aortic valve endocarditis and spondylodiscitis due to Streptococcus vestibularis were detected. The patient was successfully treated with intravenous potassium penicillin G and gentamicin for six weeks, followed by oral amoxicillin for three months, in addition to aortic valve replacement. In all patients with spondylodiscitis, infective endocarditis should be considered, particularly in patients with heart valve disease history, since spondylodiscitis may be the presenting sign of an infective endocarditis. Cardiac valve replacement surgery should be performed if the course of fever and inflammatory syndrome is unfavorable after appropriate antibiotic treatment. We report the first case with both native aortic valve endocarditis and spondylodiscitis due to Streptococcus vestibularis.
- Full Text
- View/download PDF
29. European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease
- Author
-
Michele Bartoletti, Ozlem Azap, Aleksandra Barac, Linda Bussini, Onder Ergonul, Robert Krause, Alejandro Martin-Quiros, José Ramón Paño-Pardo, Nicholas Power, Marcella Sibani, Balint Gergely Szabo, Sotirios Tsiodras, Ines Zollner-Schwetz, Jesús Rodríguez-Baño, Ergönül, Mehmet Önder (ORCID 0000-0003-1935-9235 & YÖK ID 110398), Bartoletti, M., Azap, O., Barac, A., Bussini, L., Krause, R., Martin Quiros, A., Paño-Pardo, J.R., Power, N., Sibani, M., Szabo, B.G., Tsiodras, S., Zollner-Schwetz, I., Rodríguez-Baño, J., Koç Üniversitesi İş Bankası Enfeksiyon Hastalıkları Uygulama ve Araştırma Merkezi (EHAM) / Koç University İşbank Center for Infectious Diseases (KU-IS CID), Koç University Hospital, and School of Medicine
- Subjects
Microbiology (medical) ,Nirmatrelvir/ritonavir ,Remdesivir ,Tixagevimab ,COVID-19 ,Antibodies, Monoclonal ,General Medicine ,Communicable Diseases ,Sotrovimab ,COVID-19 Drug Treatment ,Infectious Diseases ,Antineoplastic Agents, Immunological ,Cilgavimab ,ESCMID ,Molnupiravir ,Outpatients ,Medicine ,Humans - Abstract
[Scope] Despite the large availability of vaccines, coronavirus disease 2019 (COVID-19), induced by severe acute respiratory syndrome coronavirus 2, continues to be a major threat for health-care providers and fragile people. A number of options are now available for outpatients with mild-to-moderate COVID-19 at the risk of disease progression for the prevention of deaths or hospitalization., [Methods] A European Society of Clinical Microbiology and Infectious Diseases COVID-19 guidelines task force was established by the European Society of Clinical Microbiology and Infectious Diseases Executive Committee. A small group was established, half appointed by the chair and the remaining selected based on an open call. Each panel met virtually once a week. For all decisions, a simple majority vote was used. A long list of clinical questions using the population, intervention, comparison, outcome format was developed at the beginning of the process. For each population, intervention, comparison, outcome, two panel members performed a literature search, with a third panelist involved in case of inconsistent results. Voting was based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach., [Recommendations] In this update, we focus on anti-viral agents, monoclonal antibodies (mAbs) and other treatment options proposed for patients with mild or moderate COVID-19 who are at the risk of hospitalization or death. Although the use of anti-virals is recommended, especially nirmatrelvir/ritonavir and remdesivir or, alternatively, molnupirarvir, the administration of mAbs against the spike protein strictly depends on circulating variants or the ability to test timely for variants and sub-variants. At the time of writing (April–June 2022), the only active mAb was tixagevimab/cilgavimab given the predominance of the Omicron BA.2, BA.3, BA.4 and BA.5 sub-lineages in Europe. However, considering that the epidemiological scenario is extremely dynamic, constant monitoring of variants of concern is mandatory.
- Published
- 2022
30. Inappropriate use of ivermectin during the COVID-19 pandemic: primum non nocere!
- Author
-
Aleksandra Barac, Michele Bartoletti, Ozlem Azap, Linda Bussini, Onder Ergonul, Robert Krause, José Ramón Paño-Pardo, Nicholas R. Power, Jesús Rodríguez-Baño, Marcella Sibani, Balint Gergely Szabo, Sotirios Tsiodras, Paul E. Verweij, Alejandro Martín Quirós, Ines Zollner-Schwetz, Barac A., Bartoletti M., Azap O., Bussini L., Ergonul O., Krause R., Pano-Pardo J.R., Power N.R., Rodriguez-Bano J., Sibani M., Szabo B.G., Tsiodras S., Verweij P.E., Quiros A.M., and Zollner-Schwetz I.
- Subjects
Microbiology (medical) ,Ivermectin ,ESCMID guidelines ,SARS-CoV-2 ,COVID-19 ,General Medicine ,COVID-19 Drug Treatment ,Treatment ,Clinical ,Infectious Diseases ,ESCMID guideline ,Humans ,Pandemics - Abstract
NA
- Published
- 2022
31. ESCMID COVID-19 living guidelines: drug treatment and clinical management
- Author
-
Linda Bussini, Nicholas R. Power, Jesús Rodríguez-Baño, Özlem Kurt Azap, Michele Bartoletti, Onder Ergonul, Sotirios Tsiodras, Robert Krause, Marcella Sibani, Ines Zollner-Schwetz, Aleksandra Barac, Paul E. Verweij, Balint Gergely Szabo, José Ramón Paño-Pardo, Ergönül, Mehmet Önder (ORCID 0000-0003-1935-9235 & YÖK ID 110398), Bartoletti, Michele, Azap, Ozlem, Barac, Aleksandra, Bussini, Linda, Krause, Robert, Paño-Pardo, José Ramón, Power, Nicholas R, Sibani, Marcella, Szabo, Balint Gergely, Tsiodras, Sotirios, Verweij, Paul E., Zollner-Schwetz, Ines, Rodríguez-Baño, Jesús, Koç Üniversitesi İş Bankası Enfeksiyon Hastalıkları Uygulama ve Araştırma Merkezi (EHAM) / Koç University İşbank Center for Infectious Diseases (KU-IS CID), School of Medicine, Bartoletti M., Azap O., Barac A., Bussini L., Ergonul O., Krause R., Pano-Pardo J.R., Power N.R., Sibani M., Szabo B.G., Tsiodras S., Verweij P.E., Zollner-Schwetz I., and Rodriguez-Bano J.
- Subjects
lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,Guideline ,030204 cardiovascular system & hematology ,Azithromycin ,chemistry.chemical_compound ,0302 clinical medicine ,Medicine ,030212 general & internal medicine ,Letter to the Editor ,education.field_of_study ,General Medicine ,3. Good health ,Infectious Diseases ,Practice Guidelines as Topic ,Coinfection ,Human ,medicine.drug ,Microbiology (medical) ,Adult ,medicine.medical_specialty ,Secondary infection ,Population ,MEDLINE ,Guidelines ,COVID-19 ,Disease progression ,Mortality ,Treatment ,Antibodies, Monoclonal, Humanized ,Antiviral Agents ,03 medical and health sciences ,Tocilizumab ,All institutes and research themes of the Radboud University Medical Center ,Humans ,Intensive care medicine ,education ,COVID-19 Serotherapy ,Antiviral Agent ,business.industry ,SARS-CoV-2 ,Immunization, Passive ,Hydroxychloroquine ,medicine.disease ,Antibodies, Neutralizing ,Infectious ,Diseases ,Microbiology ,COVID-19 Drug Treatment ,chemistry ,business - Abstract
[Scope] In January 2021, the ESCMID Executive Committee decided to launch a new initiative to develop ESCMID guidelines on several COVID-19-related issues, including treatment of COVID-19., [Methods] An ESCMID COVID-19 guidelines task force was established by the ESCMID Executive Committee. A small group was established, half appointed by the chair, and the remaining selected with an open call. Each panel met virtually once a week. For all decisions, a simple majority vote was used. A long list of clinical questions using the PICO (population, intervention, comparison, outcome) format was developed at the beginning of the process. For each PICO, two panel members performed a literature search with a third panellist involved in case of inconsistent results. Voting was based on the GRADE approach., [Questions addressed by the guideline and recommendations] A synthesis of the available evidence and recommendations is provided for each of the 15 PICOs, which cover use of hydroxychloroquine, bamlanivimab alone or in combination with etesevimab, casirivimab combined with imdevimab, ivermectin, azithromycin and empirical antibiotics, colchicine, corticosteroids, convalescent plasma, favipiravir, remdesivir, tocilizumab and interferon β-1a, as well as the utility of antifungal prophylaxis and enoxaparin. In general, the panel recommended against the use of hydroxychloroquine, ivermectin, azithromycin, colchicine and interferon β-1a. Conditional recommendations were given for the use of monoclonal antibodies in high-risk outpatients with mild–moderate COVID-19, and remdesivir. There was insufficient evidence to make a recommendation for use of favipiravir and antifungal prophylaxis, and it was recommended that antibiotics should not be routinely prescribed in patients with COVID-19 unless bacterial coinfection or secondary infection is suspected or confirmed. Tocilizumab and corticosteroids were recommended for treatment of severe COVID-19 but not in outpatients with non-severe COVID-19., [Scope] The aim of the present guidance is to provide evidence-based recommendations for management of adults with coronavirus disease 2019 (COVID-19). More specifically, the goal is to aid clinicians managing patients with COVID-19 at various levels of severity including outpatients, hospitalized patients, and those admitted to intensive care unit. Considering the composition of the panel, mostly clinical microbiologists or infectious disease specialists with no pulmonology or intensive care background, we focus only on pharmacological treatment and do not give recommendations on oxygen supplement/support. Similarly, as no paediatricians were included in the panel; the recommendations are only for adult patients with COVID-19. Considering the current literature, no guidance was given for special populations such as the immunocompromised.
- Published
- 2021
32. The Role of AcrAB-TolC Efflux Pumps on Quinolone Resistance of E. coli ST131
- Author
-
O. Kurt-Azap, Ayşegül Yeşilkaya, Mehmet Gönen, Nazli Atac, Istar Dolapci, Fusun Can, Onder Ergonul, Ergönül, Mehmet Önder (ORCID 0000-0003-1935-9235 & YÖK ID 110398), Ataç, Nazlı, Gönen, Mehmet (ORCID 0000-0002-2483-075X & YÖK ID 237468), Kurt-Azap, O., Dolapcı, I., Yeşilkaya, A., Can, F., School of Medicine, College of Engineering, Department of Clinical Microbiology and Infectious Diseases, and Department of Industrial Engineering
- Subjects
0301 basic medicine ,medicine.drug_class ,Virulence Factors ,030106 microbiology ,Antibiotics ,Virulence ,Drug resistance ,Microbial Sensitivity Tests ,Biology ,Quinolones ,medicine.disease_cause ,Applied Microbiology and Biotechnology ,Microbiology ,03 medical and health sciences ,Drug Resistance, Multiple, Bacterial ,medicine ,Escherichia coli ,Humans ,Escherichia coli Infections ,Escherichia coli Proteins ,General Medicine ,biochemical phenomena, metabolism, and nutrition ,Anti-Bacterial Agents ,Multiple drug resistance ,Ciprofloxacin ,Multilocus sequence typing ,Efflux ,Sequence type 131 ,Urinary-tract-infections ,Multidrug-resistance ,Fluoroquinolone-resistance ,Antibiotic-resistance ,H30RX subclones ,E. COLI ,Overexpression ,Mara ,Expression ,Carrier Proteins ,medicine.drug ,Multilocus Sequence Typing - Abstract
Escherichia coli ST131 is a cause for global concern because of its high multidrug resistance and several virulence factors. In this study, the contribution of acrAB-TolC efflux system of E. coli ST131 to fluoroquinolone resistance was evaluated. A total of nonrepetitive 111 ciprofloxacin-resistant E. coli isolates were included in the study. Multilocus sequence typing was used for genotyping. Expressions of acrA, acrB, and TolC efflux pump genes were measured by RT-PCR. Mutations in marA, gyrA, parC, and aac(6)-lb-cr positivity were studied by Sanger sequencing. Sixty-four (57.7%) of the isolates were classified as ST131, and 52 (81.3%) of the ST131 isolates belonged to H30-Rx subclone. In ST131, CTX-M 15 positivity (73%) and aac(6)-lb-cr carriage (75%) were significantly higher than those in non-ST131 (12.8% and 51%, respectively) (P, NA
- Published
- 2018
33. Healthcare-associated Gram-negative bloodstream infections: Antibiotic resistance and predictors of mortality
- Author
-
Emel Yilmaz, Serda Gulsun, Cigdem Ataman Hatipoglu, Ilkay Karaoglan, Fusun Can, Y. Tezer, Hikmet Eda Alışkan, Suda Tekin, Mehtap Aydin, Gulsen Yoruk, Şebnem Erdinç, Aynur Engin, H. Cabadak, Alpay Azap, Halis Akalin, Asuman Inan, Funda Şimşek, Hüseyin Bilgin, Aysegul Yesilkaya, Şafak Kaya, Lutfiye Mulazimoglu, Özlem Kurt Azap, Onder Ergonul, Funda Timurkaynak, Turhan Togan, Seniha Başaran, Serap Şimşek Yavuz, Ebru Kurşun, Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı., Yılmaz, Emel, Akalın, Halis, AAU-8952-2020, and [Ergonul, O. -- Tekin, S. -- Can, F.] Koc Univ, Sch Med, Infect Dis & Clin Microbiol Dept, Istanbul, Turkey -- [Aydin, M. -- Timurkaynak, F.] Baskent Univ, Sch Med, Istanbul Hosp, Infect Dis & Clin Microbiol Dept, Etimesgut Ankara, Turkey -- [Azap, A.] Ankara Univ, Fac Med, Infect Dis & Clin Microbiol Dept, TR-06100 Ankara, Turkey -- [Basaran, S. -- Yavuz, S. S.] Istanbul Univ, Istanbul Med Sch, Infect Dis & Clin Microbiol Dept, Istanbul, Turkey -- [Kaya, S. -- Gulsun, S.] Diyarbakir Training & Res Hosp, Infect Dis & Clin Microbiol Dept, Diyarbakir, Turkey -- [Yoruk, G.] Istanbul Training & Res Hosp, Infect Dis & Clin Microbiol Dept, Istanbul, Turkey -- [Kursun, E. -- Aliskan, H. E.] Baskent Univ, Sch Med, Adana Hosp, Infect Dis & Clin Microbiol Dept, Adana, Turkey -- [Yesilkaya, A. -- Azap, O.] Baskent Univ, Sch Med, Ankara Hosp, Infect Dis & Clin Microbiol Dept, Ankara, Turkey -- [Simsek, F.] Okmeydani Training & Res Hosp, Infect Dis & Clin Microbiol Dept, Istanbul, Turkey -- [Yilmaz, E. -- Akalin, H.] Uludag Univ, Sch Med, Infect Dis & Clin Microbiol Dept, Bursa, Turkey -- [Bilgin, H. -- Mulazimoglu, L.] Marmara Univ, Sch Med, Infect Dis & Clin Microbiol Dept, Istanbul, Turkey -- [Hatipoglu, C. -- Erdinc, S.] Ankara Numune Training & Res Hosp, Infect Dis & Clin Microbiol Dept, Ankara, Turkey -- [Cabadak, H. -- Tezer, Y.] Ankara Specialty Hosp, Infect Dis & Clin Microbiol Dept, Ankara, Turkey -- [Togan, T.] Baskent Univ, Sch Med, Konya Hosp, Infect Dis & Clin Microbiol Dept, Konya, Turkey -- [Karaoglan, I.] Gaziantep Univ, Sch Med, Infect Dis & Clin Microbiol Dept, Gaziantep, Turkey -- [Inan, A.] Haydarpasa Numune Training & Res Hosp, Infect Dis & Clin Microbiol Dept, Istanbul, Turkey -- [Engin, A.] Cumhuriyet Univ, Sch Med, Infect Dis & Clin Microbiol Dept, Sivas, Turkey
- Subjects
0301 basic medicine ,Male ,Acinetobacter baumannii ,Pediatrics ,Turkey ,Ventilator associated pneumonia ,Klebsiella pneumoniae ,Epidemiology ,Healthcare associated infection ,Antibiotic resistance ,medicine.medical_treatment ,Bacteremia ,Bloodstream ,Piperacillin plus tazobactam ,Turkey (republic) ,0302 clinical medicine ,Controlled clinical trial ,Prevalence ,030212 general & internal medicine ,Middle aged ,Carbapenem ,APACHE ,Drug resistance, bacterial ,Surveillance ,Intensive care units ,biology ,Mortality rate ,Antibiotic agent ,Healthcare ,Klebsiella-pneumoniae ,General Medicine ,Prognosis ,Classification ,Gram-negative ,Multicenter study ,Clinical trial ,Retrospective study ,Gram-negative bacteria ,Pseudomonas aeruginosa ,Infectious diseases ,Female ,lthInfectious diseases ,Central venous catheter ,Impactenterobacteriaceae ,Human ,Microbiology (medical) ,Adult ,medicine.medical_specialty ,030106 microbiology ,Gram-negative bacterial infections ,Cephalosporin ,Gram negative bacterium ,Outcomes ,Cause of death ,Major clinical study ,Bloodstream infection ,Microbiology ,Article ,03 medical and health sciences ,Cross infection ,Intensive care ,Internal medicine ,Enterobacter cloacae ,medicine ,Escherichia coli ,Humans ,Intensive care unit ,Mortality ,Aged ,Program ,Drug effects ,business.industry ,Colistin ,Quinoline derived antiinfective agent ,Aminoglycoside antibiotic agent ,Odds ratio ,Survival analysis ,medicine.disease ,biology.organism_classification ,Nonhuman ,Beta-Lactamases ,Carbapenem-Resistant Enterobacteriaceae ,Klebsiella Pneumoniae ,Confidence interval ,Retrospective studies ,Pneumonia ,Risk factors ,Isolation and purification ,Gram negative infection ,Risk factor ,business ,Controlled study ,Public, environmental & occupational health - Abstract
WOS: 000389233700014, PubMed ID: 27717604, This article describes the prevalence of antibiotic resistance and predictors of mortality for healthcare-associated (HA) Gram-negative bloodstream infections (GN-BSI). In total, 831 cases of HA GN-BSI from 17 intensive care units in different centres in Turkey were included; the all-cause mortality rate was 44%. Carbapenem resistance in Klebsiella pneumoniae was 38%, and the colistin resistance rate was 6%. Multi-variate analysis showed that age > 70 years [odds ratio (OR) 2, 95% confidence interval (CI) 1.22-3.51], central venous catheter use (OR 2.1, 95% CI 1.09-4.07), ventilator- associated pneumonia (OR 1.9, 95% CI 1.1-3.16), carbapenem resistance (OR 1.8, 95% CI 1.11-2.95) and APACHE II score (OR 1.1, 95% CI 1.07-1.13) were significantly associated with mortality. (C) 2016 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.
- Published
- 2016
34. European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease.
- Author
-
Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, Martin-Quiros A, Paño-Pardo JR, Power N, Sibani M, Szabo BG, Tsiodras S, Zollner-Schwetz I, and Rodríguez-Baño J
- Subjects
- Humans, Antibodies, Monoclonal, Communicable Diseases, Antineoplastic Agents, Immunological, COVID-19 Drug Treatment
- Abstract
Scope: Despite the large availability of vaccines, coronavirus disease 2019 (COVID-19), induced by severe acute respiratory syndrome coronavirus 2, continues to be a major threat for health-care providers and fragile people. A number of options are now available for outpatients with mild-to-moderate COVID-19 at the risk of disease progression for the prevention of deaths or hospitalization., Methods: A European Society of Clinical Microbiology and Infectious Diseases COVID-19 guidelines task force was established by the European Society of Clinical Microbiology and Infectious Diseases Executive Committee. A small group was established, half appointed by the chair and the remaining selected based on an open call. Each panel met virtually once a week. For all decisions, a simple majority vote was used. A long list of clinical questions using the population, intervention, comparison, outcome format was developed at the beginning of the process. For each population, intervention, comparison, outcome, two panel members performed a literature search, with a third panelist involved in case of inconsistent results. Voting was based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach., Recommendations: In this update, we focus on anti-viral agents, monoclonal antibodies (mAbs) and other treatment options proposed for patients with mild or moderate COVID-19 who are at the risk of hospitalization or death. Although the use of anti-virals is recommended, especially nirmatrelvir/ritonavir and remdesivir or, alternatively, molnupirarvir, the administration of mAbs against the spike protein strictly depends on circulating variants or the ability to test timely for variants and sub-variants. At the time of writing (April-June 2022), the only active mAb was tixagevimab/cilgavimab given the predominance of the Omicron BA.2, BA.3, BA.4 and BA.5 sub-lineages in Europe. However, considering that the epidemiological scenario is extremely dynamic, constant monitoring of variants of concern is mandatory., (Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
35. Inappropriate use of ivermectin during the COVID-19 pandemic: primum non nocere!
- Author
-
Barac A, Bartoletti M, Azap O, Bussini L, Ergonul O, Krause R, Paño-Pardo JR, Power NR, Rodríguez-Baño J, Sibani M, Szabo BG, Tsiodras S, Verweij PE, Quirós AM, and Zollner-Schwetz I
- Subjects
- Humans, Ivermectin therapeutic use, Pandemics, SARS-CoV-2, COVID-19 Drug Treatment
- Published
- 2022
- Full Text
- View/download PDF
36. ESCMID COVID-19 living guidelines: drug treatment and clinical management: author's reply.
- Author
-
Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, Martín-Quirós A, Paño-Pardo JR, Power N, Sibani M, Szabo B, Tsiodras S, Zollner-Schwetz I, and Rodriguez-Baño J
- Subjects
- Humans, SARS-CoV-2, COVID-19 Drug Treatment
- Published
- 2022
- Full Text
- View/download PDF
37. Ceftazidime - Avibactam susceptibility among carbapenem-resistant Enterobacterales in a pilot study in Turkey.
- Author
-
Ozger HS, Evren E, Yildiz SS, Erol C, Bayrakdar F, Azap O, Azap A, and Senol E
- Abstract
This study aimed to detect carbapenemase genes and to determine the in vitro susceptibility of Ceftazidime-Avibactam (CZA) in Enterobacterales isolates. Carbapenemase genes were detected by polymerase chain reaction. CZA sensitivity of isolates was evaluated with broth microdilution (BMD) and disk diffusion methods. A total of 318 carbapenem-resistant Enterobacterales isolates were included. Most of the isolates (n = 290, 91.2%) were identified as Klebsiella pneumoniae. The most common carbapenemase type was OXA-48 (n = 82, 27.6%). CZA susceptibility was evaluated in 84 isolates with OXA-48 and KPC carbapenemase activity. Both BMD and disk diffusion methods revealed that 95.2% of the isolates were sensitive to CZA; whereas, 4 (4.76%) isolates were resistant to CZA. Among colistin resistant isolates, 96.5% (n = 80) of them were susceptible to CZA. Our study demonstrated high in vitro efficacy of CZA in Enterobacterales isolates producing OXA-48 carbapenemase. High susceptibility rates against colistin resistant isolates which generally are also pan drug resistant, makes CZA a promising therapeutic choice for difficult-to-treat infections. Due to its high correlation with the BMD, disk diffusion method is a suitable and more practical method in detecting CZA in vitro activity.
- Published
- 2021
- Full Text
- View/download PDF
38. Incidence and Immunologic Analysis of Coronavirus Disease (COVID-19) in Hemodialysis Patients:A Single-Center Experience.
- Author
-
Arslan H, Musabak U, Ayvazoglu Soy EH, Kurt Azap O, Sayin B, Akcay S, Haberal KM, Akdur A, Yildirim S, and Haberal M
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Betacoronavirus pathogenicity, COVID-19, Coronavirus Infections diagnosis, Coronavirus Infections immunology, Coronavirus Infections virology, Female, HLA Antigens immunology, Host-Pathogen Interactions, Humans, Incidence, Kidney Failure, Chronic diagnosis, Kidney Failure, Chronic epidemiology, Kidney Failure, Chronic immunology, Killer Cells, Natural immunology, Lymphocyte Activation, Male, Middle Aged, Opportunistic Infections diagnosis, Opportunistic Infections immunology, Opportunistic Infections virology, Pandemics, Pneumonia, Viral diagnosis, Pneumonia, Viral immunology, Pneumonia, Viral virology, Retrospective Studies, Risk Assessment, Risk Factors, SARS-CoV-2, T-Lymphocytes immunology, Treatment Outcome, Turkey epidemiology, Young Adult, Betacoronavirus immunology, Coronavirus Infections epidemiology, Immunocompromised Host, Kidney Failure, Chronic therapy, Opportunistic Infections epidemiology, Pneumonia, Viral epidemiology, Renal Dialysis adverse effects
- Abstract
Objectives: COVID-19 is a great threat to the modern world and significant threat to immunocompromised patients, including patients with chronic renal failure. We evaluated COVID-19 incidence among our hemodialysis patients and investigated the most probable immune mechanisms against COVID-19., Materials and Methods: Başkent University has 21 dialysis centers across Turkey, with 2420 patients on hemodialysis and 30 on peritoneal dialysis. Among these, we retrospectively evaluated 602 patients (257 female/345 male) with chronic renal failure receiving hemodialysis as renal replacement therapy; 7 patients (1.1%) were infected with SARS-CoV-2. We retrospectively collected patient demographic characteristics, clinical data, and immunological factors affecting the clinical course of the disease. We divided patients into groups and included 2 control groups (individuals with normal renal functions): group I included COVID-19-positive patients with normal renal function, group II included COVID-19-positive hemodialysis patients, group III included COVID-19-negative hemodialysis patients, and group IV included COVID-19-negative patients with normal renal function. Lymphocyte subsets in peripheral blood and typing of human leukocyte antigens were analyzed in all groups, with killer cell immunoglobulin like receptor genes analyzed only in COVID-19-positive patients and healthy controls., Results: No deaths occurred among the 7 COVID-19-positive hemodialysis patients. Group I patients were significantly older than patients in groups II and III (P = .039, P = .030, respectively) but not significantly different from group IV (P = .060). Absolute counts of natural killer cells in healthy controls were higherthan in other groups (but not significantly). ActivatedT cells were significantly increased in both COVID-19-positive groups versus COVID-19-negative groups. Groups showed significant differences in C and DQ loci with respect to distribution of alleles in both HLA classes., Conclusions: Although immunocompromised patients are at greater risk for COVID-19, we found lower COVID-19 incidence in our hemodialysis patients, which should be further investigated in in vitro and molecular studies.
- Published
- 2020
- Full Text
- View/download PDF
39. Promoters of Colistin Resistance in Acinetobacter baumannii Infections.
- Author
-
Nurtop E, Bayındır Bilman F, Menekse S, Kurt Azap O, Gönen M, Ergonul O, and Can F
- Subjects
- Acinetobacter Infections drug therapy, Acinetobacter baumannii drug effects, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents pharmacology, Bacterial Proteins genetics, Drug Resistance, Bacterial drug effects, Female, Humans, Male, Microbial Sensitivity Tests methods, Middle Aged, Mutation genetics, Transcription Factors genetics, beta-Lactamases genetics, Acinetobacter Infections microbiology, Acinetobacter baumannii genetics, Colistin pharmacology, Drug Resistance, Bacterial genetics, Promoter Regions, Genetic genetics
- Abstract
Objectives: We aimed to describe the mechanisms of colistin resistance in Acinetobacter baumannii . Materials and Methods: Twenty-nine patients diagnosed with colistin-resistant A. baumannii infection were included to the study. The mutations in pmrCAB , lpxA , lpxC , and lpxD genes, expression of pmrCAB , carbapenemases, and mcr-1 positivity were studied. Results: Twenty-seven (93%) of the patients received IV colistin therapy during their stay, and the case fatality rate was 45%. All mutations in pmrC and pmrB were found to be accompanied with a mutation in lpxD . The most common mutations were I42V and L150F in pmrC (65%), E117K in lpxD (65%), and A138T in pmrB (58.6%). The colistin minimum inhibitory concentrations (MICs) of the isolates having any of these four mutations were higher than the isolates with no mutations ( p < 0.001). The two most common mutations in pmrC (I42V and L150F) were found to be associated with higher expressions of pmrA and pmrC and higher colistin MIC values ( p = 0.010 and 0.031). All isolates were bla
OXA-23 positive. Conclusion: Coexistence of the lpxD mutation along with mutations in pmrCAB indicates synergistic function of these genes in development of colistin resistance in A. baumannii .- Published
- 2019
- Full Text
- View/download PDF
40. Impact of the ST101 clone on fatality among patients with colistin-resistant Klebsiella pneumoniae infection.
- Author
-
Can F, Menekse S, Ispir P, Atac N, Albayrak O, Demir T, Karaaslan DC, Karahan SN, Kapmaz M, Kurt Azap O, Timurkaynak F, Simsek Yavuz S, Basaran S, Yoruk F, Azap A, Koculu S, Benzonana N, Lack NA, Gönen M, and Ergonul O
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Gene Expression Profiling, Hospitals, Humans, Infant, Infant, Newborn, Klebsiella pneumoniae drug effects, Klebsiella pneumoniae genetics, Klebsiella pneumoniae isolation & purification, Male, Middle Aged, Multilocus Sequence Typing, Polymerase Chain Reaction, Prospective Studies, Sequence Analysis, DNA, Survival Analysis, Turkey epidemiology, Young Adult, Anti-Bacterial Agents pharmacology, Colistin pharmacology, Drug Resistance, Bacterial, Genotype, Klebsiella Infections microbiology, Klebsiella Infections mortality, Klebsiella pneumoniae classification
- Abstract
Objectives: We describe the molecular characteristics of colistin resistance and its impact on patient mortality., Methods: A prospective cohort study was performed in seven different Turkish hospitals. The genotype of each isolate was determined by MLST and repetitive extragenic palindromic PCR (rep-PCR). Alterations in mgrB were detected by sequencing. Upregulation of pmrCAB, phoQ and pmrK was quantified by RT-PCR. mcr-1 and the genes encoding OXA-48, NDM-1 and KPC were amplified by PCR., Results: A total of 115 patients diagnosed with colistin-resistant K. pneumoniae (ColR-Kp) infection were included. Patients were predominantly males (55%) with a median age of 63 (IQR 46-74) and the 30 day mortality rate was 61%. ST101 was the most common ST and accounted for 68 (59%) of the ColR-Kp. The 30 day mortality rate in patients with these isolates was 72%. In ST101, 94% (64/68) of the isolates had an altered mgrB gene, whereas the alteration occurred in 40% (19/47) of non-ST101 isolates. The OXA-48 and NDM-1 carbapenemases were found in 93 (81%) and 22 (19%) of the total 115 isolates, respectively. In multivariate analysis for the prediction of 30 day mortality, ST101 (OR 3.4, CI 1.46-8.15, P = 0.005) and ICU stay (OR 7.4, CI 2.23-29.61, P = 0.002) were found to be significantly associated covariates., Conclusions: Besides ICU stay, ST101 was found to be a significant independent predictor of patient mortality among those infected with ColR-Kp. A significant association was detected between ST101 and OXA-48. ST101 may become a global threat in the dissemination of colistin resistance and the increased morbidity and mortality of K. pneumoniae infection.
- Published
- 2018
- Full Text
- View/download PDF
41. Molecular epidemiology of bloodstream-associated Escherichia coli ST131 H30-Rx subclone infection in a region with high quinolone resistance.
- Author
-
Can F, Kurt-Azap O, Nurtop E, Ispir P, Seref C, and Ergonul O
- Abstract
Bloodstream infections caused by Escherichia coli ST131 and ST131 H30-Rx subclones have emerged worldwide. This study was carried out to evaluate the prevalence of the ST131-Rx subclone and characterize the virulence properties of the Rx isolates among the bloodstream E. coli isolates. A total of 297 non-duplicated E. coli bloodstream isolates were studied. Antibiotic susceptibilities were tested using the disc diffusion method. PCR amplification and sequencing was used to identify ST131 and H30-Rx, the virulence gene, the β-lactamase and virotype. Quinolone resistance among bacteraemic E. coli strains was 51 %, and it was 98 % among E. coli ST131 isolates. The ST131 isolates accounted for 16 % (49) of all isolates and all ST131 isolates belonged to the extraintestinal pathogenic E. coli . The proportion of H30 subclone among the ST131 isolates was 98 %, and 75 % of H30 isolates belonged to the H30-Rx subclone. The prevalence of ST131 increased from 13 to 23 % in 4 years; however, there was a decrease in the ratio of H30-Rx infections. CTX-M-15 was detected in 85 % of ST131 and all of the H30-Rx isolates. The virulence genes associated with adhesion, cell protection, iron uptake and toxins ( papA, iha, kpsMTII, iut and sat ) were more common in ST131 than in non-ST131 isolates. Most of the ST131 and H30-Rx isolates were of the C virotype. All papA -positive isolates were in virotype C. The E. coli ST131 clone has increased rapidly among bloodstream isolates. However, a decrease in the proportion of the H30-Rx subclone in the quinolone-resistant population suggests the possibility of dissemination of other virulent and quinolone-resistant subclones in hospital settings.
- Published
- 2016
- Full Text
- View/download PDF
42. Detection of OXA-48-like Carbapenemase-Producing Klebsiella pneumoniae in a Tertiary Care Center in Turkey: Molecular Characterization and Epidemiology.
- Author
-
Azap O, Otlu B, Yeşilkaya A, and Yakupoğulları Y
- Published
- 2013
- Full Text
- View/download PDF
43. [A fatal case of West Nile virus encephalitis].
- Author
-
Yeşilkaya A, Kurt Azap O, Aarslan H, Yağcı Çağlayık D, Uyar Y, Korukluoğlu G, and Ozkul A
- Subjects
- Aged, Antibodies, Viral blood, Enzyme-Linked Immunosorbent Assay, Fatal Outcome, Fever of Unknown Origin etiology, Fluorescent Antibody Technique, Humans, Immunoglobulin M blood, Male, Neutralization Tests, Seasons, Tremor etiology, Turkey, Unconsciousness etiology, West Nile Fever complications, West Nile virus immunology, West Nile Fever diagnosis
- Abstract
Although West Nile virus (WNV) serologic evidence has been well demonstrated throghout Turkey in the last 40 years; the first symptomatic WNV infection was reported in 2009 and increased number of cases were reported during August 2010. In that period WNV encephalitis was diagnosed serologically (WNV IgM positivity in serum sample detected by ELISA and IFA) and confirmed by plaque reduction neutralization test in a 76-year-old man who was admitted to Baskent University Faculty of Medicine with complaints of fever, impaired consciousness and generalized tremors. Despite all supportive treatment, he died on the 9th day of hospitalization. In this report, detailed clinical course, laboratory features and diagnosis of this mortal case of WNV encephalitis were described. WNV encephalitis should be considered in the differential diagnosis of patients with fever of unknown origin and loss of consciousness especially in summer and early fall in Turkey.
- Published
- 2012
44. Mycobacterium fortuitum Infection Presenting as Community-acquired Pneumonia in an Immunocompetent Host.
- Author
-
Kupeli E, Bozkurt E, Azap O, and Eyuboglu FO
- Abstract
Mycobacterium fortuitum is a rapidly growing environmental mycobacteria, frequently isolated from water, dust, and soil, which commonly causes infection in the presence of underlying disease or immunosuppression. Skin, soft tissue, and bones are important sites of M. fortuitum, but it may colonize in the respiratory tract as well. We report the case of an otherwise healthy man who presented with signs and symptoms of community-acquired pneumonia. He was diagnosed as having primary infection with M. fortuitum and treated with multidrug antibacterial therapy. Our case confirms that M. fortuitum poses a threat not only to patients with immune defects but also to immunocompetent hosts. Flexible bronchoscopy or a transthoracic needle aspiration may be required to confirm the diagnosis.
- Published
- 2010
- Full Text
- View/download PDF
45. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.
- Author
-
Azap OK, Arslan H, Serefhanoğlu K, Colakoğlu S, Erdoğan H, Timurkaynak F, and Senger SS
- Subjects
- Adolescent, Adult, Aged, Animals, Anti-Bacterial Agents pharmacology, Cohort Studies, DNA, Bacterial genetics, Escherichia coli Proteins classification, Escherichia coli Proteins genetics, Female, Humans, Male, Microbial Sensitivity Tests methods, Middle Aged, Polymerase Chain Reaction methods, Pregnancy, Prospective Studies, Risk Factors, Sequence Analysis, DNA, Turkey, Uropathogenic Escherichia coli drug effects, Young Adult, beta-Lactamases classification, beta-Lactamases genetics, Community-Acquired Infections microbiology, Escherichia coli Infections microbiology, Escherichia coli Proteins biosynthesis, Urinary Tract Infections microbiology, Uropathogenic Escherichia coli enzymology, Uropathogenic Escherichia coli isolation & purification, beta-Lactamases biosynthesis
- Abstract
The aim of this prospective cohort study was to determine the risk factors for community-acquired urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase (ESBL)-positive Escherichia coli and the distribution of the ESBL enzyme types. Structured forms were filled in for patients diagnosed with community-acquired UTI in four different geographical locations in Turkey. The forms and the isolates were sent to the central laboratory at Baskent University Hospital, Ankara. Antimicrobial susceptibility was determined according to the CLSI criteria. PCR and DNA sequencing were used to characterize the bla(TEM), bla(CTX-M) and bla(SHV) genes. Multivariate analysis was performed using logistic regression. A total of 510 patients with UTI caused by Gram-negative bacteria were included in this study. ESBLs were detected in 17 of 269 (6.3%) uropathogenic E. coli isolates from uncomplicated UTIs and 34 of 195 (17.4%) E. coli isolates from complicated UTIs (p <0.001). According to multivariate analysis, more than three urinary tract infection episodes in the preceding year (OR 3.8, 95% CI 1.8-8.1, p <0.001), use of a beta-lactam antibiotic in the preceding 3 months (OR 4.6, 95% CI 2.0-0.7, p <0.001) and prostatic disease (OR 9.6, 95% CI 2.1-44.8, p 0.004) were found to be associated with ESBL positivity. The percentages of isolates with simultaneous resistance to trimethoprim-sulphamethoxazole, ciprofloxacin and gentamicin were found to be 4.6% in the ESBL-negative group and 39.2% in the ESBL-positive group (p <0.001). Forty-six of 51 ESBL-positive isolates (90.2%) were found to harbour CTX-M-15. Therapeutic alternatives for UTI, particularly in outpatients, are limited. Further clinical studies are needed to guide the clinicians in the management of community-acquired UTIs.
- Published
- 2010
- Full Text
- View/download PDF
46. Prevalence of cutaneous bacterial infections and nasal carriage of Staphylococcus aureus in recipients of renal transplants.
- Author
-
Ada S, Seçkin D, Azap O, Budakoğlu I, and Haberal M
- Subjects
- Adult, Carrier State epidemiology, Carrier State immunology, Cross-Sectional Studies, Female, Humans, Male, Nasal Mucosa immunology, Prevalence, Risk Factors, Staphylococcal Skin Infections epidemiology, Staphylococcal Skin Infections immunology, Carrier State microbiology, Kidney Transplantation immunology, Nasal Mucosa microbiology, Staphylococcal Skin Infections microbiology, Staphylococcus aureus isolation & purification
- Abstract
Background: Renal transplant recipients (RTRs) often develop bacterial infections as a result of their long-term immunosuppressive treatment. However, there is no published case-control study of cutaneous bacterial infections in this population, and the prevalence of nasal Staphyloccus aureus carriage and its role in cutaneous bacterial infections in RTRs are not known., Aims: To determine whether the prevalence of cutaneous bacterial infections and nasal S. aureus carriage are increased in RTRs and to investigate the association between nasal S. aureus carriage and cutaneous staphylococcal infections., Methods: In total, 66 outpatient RTRs and 67 controls were investigated for the presence of cutaneous bacterial infections. Bacterial cultures were taken from clinically suspicious cutaneous lesions, and three nasal swabs were collected to detect nasal S. aureus colonization., Results: Cutaneous bacterial infection was suspected in 42.4% of RTRs, and in 14.2% of controls. However, of the lesions that could be cultured, microbiologically proven cutaneous bacterial [methicillin-sensitive S. aureus (MSSA)] infections were confirmed in only two RTRs and one control subject. Nasal S. aureus carriage was found in 10.6% of RTRs and 29.9% of controls (P < 0.05). Both RTRs with MSSA infection were nasal carriers, whereas nasal S. aureus carriage was not detected in the only control subject with MSSA infection. All S. aureus isolates were oxacillin-sensitive., Conclusion: Screening for nasal S. aureus carriage does not seem to assist in preventing staphylococcal bacterial infections in outpatient RTRs.
- Published
- 2009
- Full Text
- View/download PDF
47. In vitro activity of tigecycline against resistant micro-organisms isolated from burn patients.
- Author
-
Timurkaynak F, Arslan H, Azap OK, Senger SS, Başaran O, Karaman SO, and Haberal M
- Subjects
- Acinetobacter drug effects, Bacteriological Techniques, Burns drug therapy, Enterococcus drug effects, Gram-Negative Bacteria isolation & purification, Humans, Methicillin Resistance drug effects, Microbial Sensitivity Tests, Minocycline pharmacology, Staphylococcus aureus drug effects, Tigecycline, Anti-Bacterial Agents pharmacology, Burns microbiology, Drug Resistance, Multiple, Bacterial, Gram-Negative Bacteria drug effects, Minocycline analogs & derivatives
- Abstract
Infections in burn patients are usually caused by multidrug-resistant micro-organisms. Tigecycline, a derivative of glycylcyclines, is an effective antibiotic against the resistant strains. The aim of this study is to determine the in vitro activity of tigecycline against the multidrug-resistant bacteria isolated from burn patients. Fourty-seven bacteria isolated from 118 patients hospitalized in the burn unit during 2003-2006 were included in the study. Gram-negative bacteria that were resistant to at least six broad-spectrum antibiotics, methicillin-resistant staphylococci and ampicillin-resistant enterococci were studied. Minimal inhibitory concentration values of tigecycline against these bacteria were tested by E-test strips. Susceptibility breakpoints were determined according to the previous studies;
- Published
- 2008
- Full Text
- View/download PDF
48. Peritonitis due to Streptococcus anginosus in patients treated with CAPD: a report of two cases.
- Author
-
Ibis A, Sezer S, Tutal E, Azap OK, and Ozdemir FN
- Subjects
- Aged, Ampicillin therapeutic use, Anti-Bacterial Agents therapeutic use, Ciprofloxacin therapeutic use, Female, Humans, Male, Middle Aged, Peritonitis therapy, Streptococcal Infections drug therapy, Sulbactam therapeutic use, Kidney Failure, Chronic therapy, Peritoneal Dialysis, Continuous Ambulatory adverse effects, Peritonitis etiology, Streptococcal Infections complications, Streptococcus anginosus
- Published
- 2008
49. Urinary tract infections in renal transplant recipients.
- Author
-
Senger SS, Arslan H, Azap OK, Timurkaynak F, Cağir U, and Haberal M
- Subjects
- Adolescent, Adult, Anti-Bacterial Agents therapeutic use, Female, Humans, Male, Middle Aged, Postoperative Complications epidemiology, Retrospective Studies, Turkey, Bacterial Infections epidemiology, Kidney Transplantation adverse effects, Urinary Tract Infections epidemiology
- Abstract
Urinary tract infection (UTI) is the most common infectious complication following renal transplantation. The purposes of this study were to determine the causative agents of UTIs among renal transplant recipients and to compare the antibiotic susceptibilities of Escherichia coli strains isolated from renal transplant recipients and complicated community-acquired UTIs. We evaluated 75 episodes of 63 recipients with confirmed UTI who underwent transplantation during the period 1981 to 2006 at our center. Medical records of the patients were reviewed retrospectively. To compare the susceptibility rates of E coli, 226 isolates from nontransplant patients with complicated community-acquired UTIs were also evaluated. Ten episodes (13.3%) occurred in the first month following the transplantation, 11 (14.7%) in the period of the second month to the sixth month, and 54 (72%) after the sixth month of transplantation. Forty-six (61.3%) isolates were E coli. Among these isolates, ciprofloxacin resistance rates were 50% (2/4) in the first month after transplantation, 75% (6/8) in the period of the second month to the sixth month, and 32.4% (11/34) beyond 6 months after transplantation. The resistance rates of trimethoprim/sulfamethoxazole (TMP-SMX) in the same time periods were 100% (4/4), 87.5% (7/8), and 70.6% (24/34), respectively. The rates of resistance to TMP-SMX among E coli isolated from renal recipients were significantly higher than those in community-acquired complicated UTIs. The increased resistance of urinary pathogens to this agent is a major concern. Although high resistance rates of ciprofloxacin against E coli strains were determined in this group, it was not found to be statistically significant.
- Published
- 2007
- Full Text
- View/download PDF
50. [Biofilm production and antifungal susceptibility patterns of Candida species isolated from hospitalized patients].
- Author
-
Demirbileki M, Timurkaynak F, Can F, Azap O, and Arslan H
- Subjects
- Amphotericin B pharmacology, Caspofungin, Drug Resistance, Fungal physiology, Echinocandins pharmacology, Fluconazole pharmacology, Humans, Itraconazole pharmacology, Lipopeptides, Microbial Sensitivity Tests, Antifungal Agents pharmacology, Biofilms growth & development, Candida drug effects, Candida physiology, Candidiasis microbiology, Fungemia microbiology
- Abstract
Biofilm producing Candida species are known to be more resistant to immune response and antimicrobial agents which leads to treatment failure. The aim of this study was to investigate the biofilm production among Candida species that were isolated from hospitalized patients and to compare the in vitro activities of antifungal agents with biofilm production. A total of 116 Candida spp. (79 C. albicans and 37 non-albicans Candida spp.) isolated from various specimens (blood, sterile body fluids, mucosal and skin lesion samples) were included to the study. Fluconazole, itraconazole, amphotericin B and caspofungin susceptibilities of the isolates were determined by broth microdilution method according to CLSI M27-A2 standards. Biofilm production of Candida spp. was determined by microplate method, using brain heart infusion broth supplemented with 0.25% glucose as a growth medium. Biofilm formation was detected in 33 of 116 isolates (28%) and 11 of them (33%) were the strains isolated from hemocultures. Biofilm production was determined more commonly in blood isolates than the strains isolated from other samples (p < 0.05). The biofilm production rate of non-albicans Candida species (41%) was found higher than C. albicans (23%), which the difference was statistically significant (p < 0.05). Amphotericin B and caspofungin were found the most effective antifungals with the MIC90 values of 0.06 microg/ml and 0.5 microg/ml for C. albicans, and 0.5 microg/ml and 1 microg/ml for non-albicans Candida species respectively. The observed positive correlation between the biofilm production and amphotericin B MIC values were found significant (p < 0.05). In conclusion, high biofilm production rates of Candida species may explain the increase in the rate of catheter-related Candida infections.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.